SEMINAR: Fibrotech: molecules to man and beyond

Darren is currently CEO and Managing Director of Occurx and has more than 20 years of management and research experience in the life sciences sector, particularly relating to drug development.

Darren is also a Professor & Director of Biomedical Research in the Department of Medicine at The University of Melbourne, St Vincent's Hospital Melbourne, and an Entrepreneur in Residence with Brandon Capital.

He was a Founder, CEO & Director of Fibrotech Therapeutics, a company developing orally active anti-fibrotic inhibitors to treat underlying pathological fibrosis in kidney and heart failure. Fibrotech was sold to Shire Plc for a record 75 million USD upfront including milestone payments up to 560m USD.

His scientific expertise lies in progressing pre-clinical novel interventions and developing experimental models of cardiovascular disease. He has published over 200 manuscripts in the field of translational research and novel interventions many of which have had a direct impact on human disease. Darren was awarded the prestigious TJ Neale award in 2009 for outstanding contribution to nephrology.

Dr Kelly has a PhD from the University of Melbourne, and is also a member of the Australian Institute of Company Directors, Ausbiotech, BioMelbourne network and a Fellow of the American Society of Nephrology.